Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation

Liver Transplantation

Volumn 17, Issue 7, 2011, Pages 798-808

  Sebagh, Mylãne ^a,b   Azoulay, Daniel ^a,b   Roche, Bruno ^a   Hoti, Emir ^a   Karam, Vincent ^a   Teicher, Elina ^a   Bonhomme Faivre, Laurence ^a   Saliba, Faouzi ^a   Duclos Vallée, Jean Charles ^a,b   Samuel, Didier ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DISEASE COURSE; DRUG SUBSTITUTION; ENDOTHELIUM; FEMALE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MALE; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; BIOPSY; FEMALE; GRAFT REJECTION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79959842617     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22282     Document Type: Article

References (39)

1. Hubscher SG,. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl 2008; 14: 596-600. (Pubitemid 351696268)
2. Dhillon AP, Burroughs AK, Hudson M, Shah N, Rolles K, Scheuer PJ,. Hepatic venular stenosis after orthotopic liver transplantation. Hepatology 1994; 19: 106-111. (Pubitemid 24020479)
3. Fiel MI, Schiano TD, Klion FM, Emre S, Hytiroglou P, Ishak KG, et al. Recurring fibro-obliterative venopathy in liver allografts. Am J Surg Pathol 1999; 23: 734-737. (Pubitemid 29262839)
4. Izaki T, Inomata Y, Asonuma K, Okajima H, Ohshiro H, Ueno M, et al. Early graft failure due to a veno-occlusive disease after a pediatric living donor liver transplantation. Pediatr Transplant 2004; 8: 301-304. (Pubitemid 38788559)
5. Martins A, Monteiro E, Freire A, Carvalho A, Veloso J, Morbey A, et al. Hepatic veno-occlusive disease after liver transplantation: an unusual case report. Transpl Int 2007; 20: 1072-1073. (Pubitemid 350043844)
6. Mion F, Cloix P, Boillot O, Gille D, Bouvier R, Paliard P, Berger F,. Veno-occlusive disease after liver transplantation. Association of acute cellular rejection and toxicity of azathioprine [in French]. Gastroenterol Clin Biol 1993; 17: 863-867. (Pubitemid 24011063)
7. Mor E, Pappo O, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R, Ben-Ari Z,. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 2001; 72: 1237-1240. (Pubitemid 33026601)
8. Nakazawa Y, Chisuwa H, Mita A, Ikegami T, Hashikura Y, Terada M, et al. Life-threatening veno-occlusive disease after living-related liver transplantation. Transplantation 2003; 75: 727-730. (Pubitemid 36337376)
9. Sebagh M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V, et al. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999; 30: 1144-1150. (Pubitemid 29510851)
10. Senzolo M, Patch D, Cholongitas E, Triantos C, Marelli L, Stigliano R, et al. Severe venoocclusive disease after liver transplantation treated with transjugular intrahepatic portosystemic shunt. Transplantation 2006; 82: 132-135. (Pubitemid 44296989)
11. Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwig J, Lake J,. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806-810.
12. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
13. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792-799. (Pubitemid 30118655)
14. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC,. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl 2008; 14: 625-632. (Pubitemid 351696273)
15. Neil DA, Hubscher SG,. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983.
16. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ,. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749. (Pubitemid 46683930)
17. Wilson CH, Agarwal K, Carter V, Burt AD, Hubscher S, Talbot D, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988-989. (Pubitemid 44564051)
18. Haga H, Egawa H, Shirase T, Miyagawa A, Sakurai T, Minamiguchi S, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 16-27. (Pubitemid 38885888)
19. Fisher A, Mor E, Hytiroglou P, Emre S, Boccagni P, Chodoff L, et al. FK506 hepatotoxicity in liver allograft recipients. Transplantation 1995; 59: 1631-1632.
20. Hytiroglou P, Lee R, Sharma K, Theise ND, Schwartz M, Miller C, Thung SN,. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. Transplantation 1993; 56: 1389-1394. (Pubitemid 24018792)
21. Tsamandas AC, Jain AB, Felekouras ES, Fung JJ, Demetris AJ, Lee RG,. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 1997; 64: 252-257. (Pubitemid 27332668)
22. Shah S, Budev M, Blazey H, Fairbanks K, Mehta A,. Hepatic veno-occlusive disease due to tacrolimus in a single-lung transplant patient. Eur Respir J 2006; 27: 1066-1068. (Pubitemid 44911123)
23. Vallet-Pichard A, Rerolle JP, Fontaine H, Larousserie F, Peraldi MN, Kreis H, Pol S,. Veno-occlusive disease of the liver in renal transplant patients. Nephrol Dial Transplant 2003; 18: 1663-1666. (Pubitemid 36939646)
24. Schiano TD, Kotler DP, Ferran E, Fiel MI,. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536-2540. (Pubitemid 47631766)
25. Firpi RJ, Nelson DR,. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006: 375-380.
26. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004.
27. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893-1899. (Pubitemid 29247066)
28. Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159-1165. (Pubitemid 37407984)
29. Fernandez I, Ulloa E, Colina F, Abradelo M, Jimenez C, Gimeno A, et al. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl 2009; 15: 948-955.
30. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56: 237-242.
31. Merli M, Gentili F, Giusto M, Attili AF, Corradini SG, Mennini G, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009; 41: 345-349.
32. Devarbhavi H, Abraham S, Kamath PS,. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl 2007; 13: 1552-1556. (Pubitemid 350168196)
33. Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R,. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20 (1 Pt 1): 88-94. (Pubitemid 24196495)
34. Krasinskas A,. The significance of nodular regenerative hyperplasia in the transplanted liver. Liver Transpl 2007; 13: 1496-1497. (Pubitemid 350168186)
35. Slapak GI, Saxena R, Portmann B, Gane E, Devlin J, Calne R, Williams R,. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25: 195-202. (Pubitemid 27015010)
36. Huang R, Schiano TD, Amolat MJ, Miller CM, Thung SN, Saxena R,. Hepatocellular proliferation and changes in microarchitecture of right lobe allografts in adult transplant recipients. Liver Transpl 2004; 10: 1461-1467. (Pubitemid 40028377)
37. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157-168.
38. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744. (Pubitemid 28355454)
39. Lerut JP, Goffette P, Molle G, Roggen FM, Puttemans T, Brenard R, et al. Transjugular intrahepatic portosystemic shunt after adult liver transplantation: experience in eight patients. Transplantation 1999; 68: 379-384. (Pubitemid 29384105)